<DOC>
	<DOCNO>NCT00050648</DOCNO>
	<brief_summary>This study compare efficacy analyze cellular effect anti-TAC ( Daclizumab ) Cyclosporine treatment psoriasis vulgaris . This three-armed study-Daclizumab alone , Cyclosporine alone , combination Daclizumab Cyclosporine .</brief_summary>
	<brief_title>To Study Effects CD25 Low Dose Cyclosporin Treatment Active Psoriasis Vulgaris</brief_title>
	<detailed_description>The purpose study safety effectiveness new drug call `` anti-TAC '' ( anti-CD25 ) Monoclonal Antibody use together low dose Cyclosporine treatment psoriasis . While exact cause psoriasis unknown , believe involve white blood cell call lymphocyte , become activated skin . It believe activated cell responsible change see rash psoriasis . Anti-TAC ( anti-CD25 ) Monoclonal Antibody design block activation lymphocyte . Because anti-TAC ( anti-CD25 ) Monoclonal Antibody target specific cell involve symptom psoriasis , new drug may better way treat psoriasis . The second drug , Cyclosporine , FDA-approved drug treatment psoriasis . There evidence laboratory Cyclosporine anti-TAC , use together , additive effect . An additional benefit study use low dose cyclosporine usually give use alone use together anti-TAC . This reduce side effect usually see high dos Cyclosporine use single drug psoriasis . The purpose study test safety effectiveness anti-TAC ( Monoclonal Antibody low dose cyclosporine patient active , moderate severe psoriasis vulgaris . We also hope gain information anti-TAC work body</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Daclizumab</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Inclusion criterion 1 . Male female patient chronic psoriasis vulgaris ( disease stable worsen &gt; 6 month ) . Patients age 16 21 consider case case basis . Patients 18 need parental consent . 2 . Extensive skin involvement . 3 . Scale , thickness , erythema individual psoriasis lesion least intensity . 4 . Psoriasis treat emollient 2 week prior treatment 5 . Patients active psoriatic arthritis , accompany psoriasis vulgaris involve 5 % body surface . 6 . History psoriasis treat topical agent previous systemic/ photo ( chemo ) therapy agent . 1. . Positive serology HIV , Hepatitis B , Hepatitis C. 2. . Positive βHCG titer . For woman childbearing potential , unwillingness inability use contraceptive device study negative βHCG . 3 . Guttate psoriasis , pustular psoriasis , whole body erythroderma . 4 . Active infection persistent fever unknown origin . 5 . ) Major concurrent illness , could worsen follow treatment DaclizumabTM . 6 ) Any history untreated neoplasm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>Daclizumab</keyword>
	<keyword>Cyclosporin</keyword>
	<keyword>anti-TAC</keyword>
	<keyword>dermatology</keyword>
	<keyword>skin</keyword>
</DOC>